Dr Jennifer David discusses the use of cysteamine 5% as a novel first line non‑hydroquinone treatment option bridging that gap between safety and efficacy in treating hyperpigmentation Disorders of hyperpigmentation,

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field